Compatibility «Amlodipine+Losartane» and «Dexa-Gentamicin»

• Interactions Amlodipine+Losartane with Dexa-Gentamicin

  • Dangerous interactions
    • ⓘ Calcium channel blockers(C08) + Drugs that cause hypokalemia; Glucocorticosteroids (C03A, A01AB04,J02AA01,H02,D07 => Increases the likelihood of ventricular tachycardia and ventricular fibrillation. (A dangerous combination, it is necessary to eliminate hypokalemia before use).
    • ⓘ Regardless of the status of the CYP3A5 genotype, the possibility of interaction with these drugs cannot be excluded.
    • ⓘ The AUC of the active metabolite after oral administration of losartan was not affected by erythromycin, a CYP3A4 inhibitor, but the AUC of losartan increased by 30%.
  • Negative interactions
    • ⓘ Inhibitors of the CYP3A4 isoenzyme.
    • ⓘ Nevertheless, strong inhibitors of the CYP3A4 isoenzyme (for example, ketoconazole, itraconazole, ritonavir) may increase the concentration of amlodipine in blood plasma to a greater extent.
    • ⓘ With the simultaneous use of amlodipine and inhibitors of the CYP3A4 isoenzyme, the symptoms of arterial hypotension and edema should be regularly monitored.
    • ⓘ Clarithromycin (inhibitor of the CYP3A4 isoenzyme).
    • ⓘ Blood pressure should be monitored, and the possibility of dose adjustment of amlodipine during and after simultaneous administration should be considered, especially with strong inducers of the CYP3A4 isoenzyme (for example, rifampicin and St. John's wort preparations).
    • ⓘ However, a 3-fold increase in plasma exposure to tacrolimus was reported in a kidney transplant patient (non-CYP3A5 expressor) after starting amlodipine for the treatment of post-transplant hypertension, which led to a decrease in the dose of tacrolimus.
    • ⓘ Reduction of the antihypertensive effect of amlodipine (due to fluid retention and sodium ions as a result of the action of corticosteroids).
    • ⓘ Caution should be exercised when using dexamethasone (CYP3A4 inducer) with amlodipine at the same time due to a possible increase in hepatic metabolism of amlodipine (CYP3A4 substrate).
    • ⓘ Caution should be exercised and the therapeutic response monitored when using CYP3A4 inducers, such as dexamethasone, with amlodipine (CYP3A4 substrate), etc.; an increase in hepatic metabolism of amlodipine is possible.
  • No interactions
    • ⓘ Since amlodipine is a weak inhibitor of CYP3A4, the exposure of mTOR inhibitors may increase when used together.
    • ⓘ The conversion of losartan into its active metabolite after intravenous administration is not affected by ketoconazole, a CYP3A4 inhibitor.
  • Positive interactions
    • ⓘ A prospective study involving healthy volunteers from China (n=9), CYP3A5 expressers, showed an increase in tacrolimus exposure by 2.5-4 times when used concomitantly with amlodipine compared with the use of tacrolimus alone.
    • ⓘ An increase in the dose of amlodipine may be required.
  • Unclear interactions
    • ⓘ Inducers of the CYP3A4 isoenzyme.
    • ⓘ With the simultaneous use of inducers of the CYP3A4 isoenzyme, the concentration of amlodipine may vary.
    • ⓘ This result was not observed in individuals who did not express CYP3A5 (n=6).
    • ⓘ Corticosteroids (mineral.
    • ⓘ And glucocorticosteroids), tetracosactide.
    • ⓘ Amiodarone, amlodipine + amiodarone.
    • ⓘ These data suggest that the conversion of losartan to its active metabolite is mediated primarily by CYP2C9 rather than CYP3A4.
    • ⓘ Corticosteroids, ACTH.
    • ⓘ Amphotericin B (for parenteral administration), corticosteroids, ACTH, stimulating laxatives or glycyrrhizin (found in licorice).

Decoding the colors of interactions and contraindications

Dangerous	—	a pronounced negative interaction or contraindication.
Negative	—	negative interaction or side effect that may reduce effectiveness.
Positive	—	the interaction can SOMETIMES be used as a positive (often a dose adjustment is needed), or it is an indication.
No	—	the drugs do NOT interact, which is separately indicated in the instructions.
Unclear	—	the system failed to pre-assess the danger.

Video instruction

▶

Look at ▶Youtube

Additional information

• Kiberis checks interactions and evaluates drug compatibility for free online right in the instructions thanks to the latest artificial intelligence technologies. The accuracy of finding is more than 95%, the accuracy of the hazard assessment is more than 80%. The online medical service takes into account all the drug groups of the selected drugs and all their components. And since the database contains 25,000 drugs with detailed instructions, not every pharmacologist can compete with our artificial intelligence. List of popular interactions.
• Why do I need to
  • Avoid dangerous prescriptions for your patients.
  • Check the contraindications.
  • Evaluate the safety of therapy in the treatment of children.
  • See the compatibility of drugs with alcohol (enter it as a drug).
  • Point the doctor to the found interaction - you may need to adjust the therapy.
  • Do you need an API for interactions/drug analogues for your project? Write to us.
• The use of information about interactions is only possible as an introduction. This information should not be used to adjust therapy without consulting a specialist.
• The article is written: artificial intelligence Kiberis
• Sources: official instructions for medicines and their active substances, as well as inter-group interactions described in medical studies and textbooks.
• Total analyzed: 170,028,852 possible combinations of drugs and their components were found 412,565 interacting combinations.
• Medicine section: Standard evidence-based medicine
• The date of the last update of the interaction database: 2026-01-22

Category - medicine